Patrick Mehlen is director of the Institut Rabelais for Interdisciplinary Research on Cancer, director of the “Laboratoire d’Excellence” DEVweCAN, deputy-director of the Research Cancer Center of Lyon, director of the Department of Translational Research and Innovation in Léon Bérard Comprehensive Cancer Center in Lyon, France and co-founder & CEO of NETRIS Pharma.
He is Adjunct Professor at the Buck Institute for Age Research, California. He has published over 150 peer-reviewed scientific publications and has received several awards including the silver medal from CNRS and the Pius XI Gold Medal from Pontificia Academia Scientiarum.
Prof. Mehlen was elected EMBO member in 2006 and member of the French Academy of Sciences in 2013.



Agnès Bernet is Professor of cancer biology at the University Claude Bernard Lyon I.

Co-founder of NETRIS Pharma, she led within the Laboratory of Apoptosis, Cancer and Development, the research team that validated the use of interference ligand/dependence receptors as novel targeted therapies for oncology.

Agnès Bernet was nominated to the “Institut Universitaire de France”, which recognizes the best French academic researchers and has followed a course of entrepreneurship at the Lyon Management School and at Boston Babson College (USA).



PharmD by training, Jordan Guyon leads non-clinical and clinical operations for NETRIS Pharma’s programs, executing the transition from preclinical to clinical stage. His activities also encompass the support in company financing processes and overall business management.

He received his Doctor of Pharmacy degree from the Faculty of Pharmacy of Lyon and graduated with a Specialized Master in Entrepreneurship from EM Lyon Business School.

Before joining NETRIS Pharma, Jordan Guyon worked on business modeling and economic valuation at Merck KGaA.




Michael has twenty years pharma and biotech industry experience with LION Bioscience, ALTANA Pharma, Sandoz and Roche in the areas of Drug Discovery, Strategic Planning, Sales and Business Development. Most recently he was responsible for CVMET Partnering in Roche, and thereafter assumed the role of CEO of Algobate AG, a privately financed Biotech company in Basel in the field of pain and gastroenterology.

Michael obtained his PhD in Biochemistry at the Max Planck Institute for Evolutionary Anthropology in Leipzig with Prof. Svante Pääbo.



Christophe is dedicating his energy and passion to life-science start-up companies as Director of Eclosion since 2008 and General Partner of Eclosion2 Investment Fund. He is also contributing his experience in managing finance and legal activities and served as CFO for companies including GeNeuro, GenKyoTex and DepGen, raising over CHF 150m in equity. He serves as Board Member of Geneuro and Chairman of its Audit Committee.

Prior to joining Eclosion, he held various corporate finance positions including CFO of a European listed company and previously manager with KPMG-Salustro, building organizations and performing M&A transactions and two IPOs. Christophe is a graduate from EDHEC Business School and from Harvard Business School. He also holds a postgraduate degree in Finance and Accounting (DESCF).


Senior Clinical Advisor

Since 2015 Josi is an independent clinical advisor and became a member of leading international regulatory and drug development networks. Her strategic focus is the clinically-driven stage-gate planning for biopharmaceutical companies, resulting in the successful transition of lead candidates into clinical development and product registration.

Josi has over 20 years’ experience in pharmaceutical drug development in Europe and in North America. Josi held executive managerial positions in international Biotech companies (Ablynx NV, GPC-Biotech, U3 Pharma) and Pharma organisations (Gilead Sciences, Bristol-Myers Squibb, OSI Pharmaceuticals, LEO Pharma).